Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
Table 1
Clinicopathological data of the study cohort.
(% of evaluated samples)
% of all patients/samples
Number of patients
61
Number of samples
81
Age (years)
Median
65
range
39–84
Sex
Male
40 (65.6)
Female
21 (34.4)
Histologic grade ()
Well-differentiated/G1
0
Moderately differentiated/G2
38 (56.7)
46.9
Poorly differentiated/G3
29 (43.3)
35.8
UICC stage ()
IA
0
IB
1 (2.3)
1.6
IIA
8 (18.6)
13.1
IIB
13 (30.2)
21.3
III
7 (16.3)
11.5
IV
14 (32.6)
22.9
Tissue of origin ()
Primary tumor
35 (43.2)
43.2
Metastasis
46 (56.8)
56.8
Smoking habits ()
Smoker
8 (20)
13.1
Nonsmoker/never smoked
32 (80)
52.5
Diabetes ()
Diabetic
17 (40.5)
27.9
Nondiabetic
25 (59.5)
41
Adjuvant CTx (Gemcitabine; )
Yes
21 (47.7)
34.4
No
23 (52.3)
37.7
Palliative CTx ()
Yes
53 (86.9)
86.9
No
8 (13.1)
13.1
Palliative RTx ()
Yes
6 (13.3)
9.8
No
39 (86.7)
63.9
KRAS codon 12/13 mutation ()
Yes
32 (57.1)
52.5
No
24 (42.9)
39.3
PSMA expression in tumor cells ()
Absent
54 (94.7)
88.5
Weak/moderate
3 (5.3)
4.9
Strong
0
PSMA expression in tumor-associated neovasculature ()
